About Trophogen
Trophogen is a Healthcare company based in Rockville (United States) founded in 2001 by Bruce Weintraub and Mariusz Szkudlinski. Biosimilars and biobetters for reproduction and cancer therapy are developed. It operates on a Professional Services and Licensing Model model. Its chief executive, as recorded, is Bruce Weintraub. Trophogen offers products and services including Human FSH Super-Agonist Analog, Human TSH Super-Agonist Analog, Bovine FSH Super-Agonist Analog, and Equine CG Super-Agonist Analog. Its focus areas include Biotechnology and Protein Engineering. Its legal entity is Trophogen Inc. Its competitors include Agile Therapeutics, Auxilium Pharmaceuticals and Xanodyne Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Trophogen Inc. is engaged in developing patented superagonist analogs of glycoprotein hormones and growth factors for human and animal health. The company addresses multi-billion dollar markets in infertility, elective egg banking, and aggressive cancers. Its BioSuperior platform technologies are designed to surpass current BioBetters and BioSimilars in imaging, diagnostics, and therapeutics. Products for human health include FSH, TSH, and VEGF analogs, while animal health solutions involve bovine FSH and equine CG analogs. The company collaborates with industry leaders like Zoetis for veterinary applications.
- Headquarters Rockville, United States
- Founders Bruce Weintraub, Mariusz Szkudlinski
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website trophogen.com
- Social LinkedIn X Facebook
- Legal Name Trophogen Inc.
- Latest Funding Round$1.84M (USD), Grant
Aug 2018
- InvestorsNIH
& 3 more
Products & Services of Trophogen
Trophogen offers a comprehensive portfolio of products and services, including Human FSH Super-Agonist Analog, Human TSH Super-Agonist Analog, Bovine FSH Super-Agonist Analog, and Equine CG Super-Agonist Analog.
Used for infertility treatment and egg banking.
Applied in imaging and treating thyroid cancer.
Licensed for superovulation in beef and dairy cows.
Used for estrus synchronization in pigs and animals.
Funding Insights of Trophogen
- Total Rounds 23
- Last Round Grant — $1.84M
- Investors Count 4
Latest 10 of 23 funding rounds of Trophogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $1.84M | Grant | – | – | |
| Mar 2018 | $2.07M | Grant | – | – | |
| Sep 2017 | $1.6M | Grant | – | – | |
| Jul 2015 | $756,000 | Grant | – | – | |
| Nov 2013 | $283,958 | Grant | – | – | |
| May 2013 | $1.87M | Grant | – | – | |
| Sep 2012 | $150,000 | Grant | – | – | |
| Sep 2012 | $150,000 | Grant | – | – | |
| Sep 2011 | $2.92M | Grant | – | – | |
| Sep 2011 | $1.94M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Trophogen
Trophogen has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| toucancapital.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Trophogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Trophogen
2 people are tracked at Trophogen (2 in leadership).
| Name | Role | Group |
|---|---|---|
Bruce Weintraub | Co-Founder & CEO | Leadership |
Mariusz Szkudlinski | Co-Founder & CSO | Leadership |
Complete people profiles for Trophogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Trophogen
3 dated milestones of Trophogen across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Trophogen is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $1.8M.
Competitors of Trophogen
Trophogen has 3 listed competitors in our database, 3 of them funded. They include Agile Therapeutics, Auxilium Pharmaceuticals and Xanodyne Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| agiletherapeutics.com | 1997 | Princeton, United States | $123.06M | Therapeutics for women's healthcare are developed and offered. | ||
| auxilium.com | 1999 | Philadelphia, United States | $43M | Developer of therapeutics and drug-device combinations for urology and sexual health | ||
| xanodyne.com | 2001 | Florence, United States | $175.78M | 6 | Developer of drugs for women's health and pain management |
Detailed competitors of Trophogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Trophogen
Websites that share an audience with Trophogen (trophogen.com).
Websites whose visitors overlap most with Trophogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
parp-inhibitors.com | parp-inhibitors.com | 100% | – | ||
ovca.org | ovca.org | 61% | – | ||
cancer.about.com | cancer.about.com | 61% | – | ||
clearityfoundation.org | clearityfoundation.org | 60% | #9,308,643 | – | |
tc-cancer.com | tc-cancer.com | 60% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Trophogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Women's Health & Fertility
3 companies that operate in the same segment as Trophogen (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | ||
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | 861 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Trophogen
Trophogen was founded in 2001.
Trophogen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Bruce Weintraub is the CEO of Trophogen, as recorded in our data. They have also founded this company.
Trophogen Inc. is engaged in developing patented superagonist analogs of glycoprotein hormones and growth factors for human and animal health. The company addresses multi-billion dollar markets in infertility, elective egg banking, and aggressive cancers. Its BioSuperior platform technologies are designed to surpass current BioBetters and BioSimilars in imaging, diagnostics, and therapeutics. Products for human health include FSH, TSH, and VEGF analogs, while animal health solutions involve bovine FSH and equine CG analogs. The company collaborates with industry leaders like Zoetis for veterinary applications.
Trophogen's top competitors include Agile Therapeutics, Auxilium Pharmaceuticals and Xanodyne Pharmaceuticals.
Trophogen offers Human FSH Super-Agonist Analog, Human TSH Super-Agonist Analog, Bovine FSH Super-Agonist Analog, and Equine CG Super-Agonist Analog.
Trophogen has 4 investors. Key investors include NIH, HHS, National Cancer Institute, and Toucan Capital.
Trophogen operates through Trophogen Inc..